ADAR1 Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

ADAR1 Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-38,566	Closed	-$1.53M	–	293
2026 Q1	$1.53M	Hold	38,566	–	–	0.09%	132
2025 Q4	$965K	Sell	38,566 -15,100	-28%	-$382K	0.07%	134
2025 Q3	$1.3M	Sell	53,666 -243,100	-82%	-$4.32M	0.12%	95
2025 Q2	$3.9M	Buy	296,766 +80,600	+37%	+$1.02M	0.6%	40
2025 Q1	$3.11M	Buy	216,166 +62,139	+40%	+$1.02M	0.58%	48
2024 Q4	$2.58M	Buy	154,027 +130,725	+561%	+$2.17M	0.52%	43
2024 Q3	$373K	Sell	23,302 -229,895	-91%	-$2.82M	0.06%	130
2024 Q2	$2.29M	Buy	253,197 +46,341	+22%	+$440K	0.43%	39
2024 Q1	$2.34M	Buy	+206,856	New	+$1.96M	0.53%	37

ADAR1 Capital Management's CNTA Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 38,566 shares — an estimated $1.53M sold.

ADAR1 Capital Management first reported a position in CNTA in Q1 2024 and held it in 9 quarters. The position peaked at $3.9M in Q2 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

ADAR1 Capital Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
ADAR1 Capital Management sold 38,566 Centessa Pharmaceuticals shares in Q2 2026, an estimated $1.53M.
ADAR1 Capital Management first reported a position in Centessa Pharmaceuticals in Q1 2024 and held it in 9 quarters.
ADAR1 Capital Management's Centessa Pharmaceuticals position peaked at $3.9M in Q2 2025.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.